Nancy Olivieri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11620033/publications.pdf

Version: 2024-02-01

29 papers	5,905 citations	236833 25 h-index	477173 29 g-index
30 all docs	30 docs citations	30 times ranked	3839 citing authors

#	Article	IF	Citations
1	Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 38.	1.6	47
2	Increased leucocyte apoptosis in transfused Î²â€thalassaemia patients. British Journal of Haematology, 2013, 160, 399-403.	1.2	7
3	Beliefs about chelation among thalassemia patients. Health and Quality of Life Outcomes, 2012, 10, 148.	1.0	28
4	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology, 2011, 86, 433-436.	2.0	63
5	Relationship between Chronic Transfusion Therapy and Body Composition in Subjects with Thalassemia. Journal of Pediatrics, 2010, 157, 641-647.e2.	0.9	28
6	Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. British Journal of Haematology, 2009, 146, 546-556.	1.2	153
7	Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem. Journal of Bone and Mineral Research, 2009, 24, 543-557.	3.1	189
8	Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood, 2009, 114, 4632-4638.	0.6	98
9	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	1.1	210
10	Inflammation and oxidant-stress in Â-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, 93, 817-825.	1.7	67
11	Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. American Journal of Hematology, 2007, 82, 255-265.	2.0	149
12	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	0.6	636
13	Effect of Long-term Transfusion on Growth in Children with Sickle Cell Anemia: Results of the Stop Trial. Journal of Pediatrics, 2005, 147, 244-247.	0.9	78
14	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	3.8	741
15	Stroke risk in siblings with sickle cell anemia. Blood, 2003, 101, 2401-2404.	0.6	98
16	Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion, 2001, 41, 1086-1092.	0.8	296
17	HSC clinical trials controversy continues. Nature Medicine, 1999, 5, 3-3.	15.2	7
18	Stroke Prevention Trial in Sickle Cell Anemia. Contemporary Clinical Trials, 1998, 19, 110-129.	2.0	228

#	Article	IF	Citations
19	5 Thalassaemia: clinical management. Best Practice and Research: Clinical Haematology, 1998, 11, 147-162.	1.1	28
20	Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler Ultrasonography. New England Journal of Medicine, 1998, 339, 5-11.	13.9	1,699
21	Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. Journal of Pediatrics, 1995, 126, 896-899.	0.9	346
22	Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator. Journal of Clinical Pharmacology, 1994, 34, 944-949.	1.0	79
23	Iron overload cardiomyopathies: New insights into an old disease. Cardiovascular Drugs and Therapy, 1994, 8, 101-110.	1.3	128
24	Clinical use of the Medication Event Monitoring System: A new window into pediatric compliance. Clinical Pharmacology and Therapeutics, 1992, 52, 102-103.	2.3	21
25	Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical Pharmacology and Therapeutics, 1991, 50, 294-298.	2.3	51
26	Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clinical Pharmacology and Therapeutics, 1990, 47, 478-482.	2.3	30
27	Saudi Arabian Sickle Cell Anemia.. Annals of the New York Academy of Sciences, 1989, 565, 143-151.	1.8	9
28	Molecular Analysis of the High-Hemoglobin-F Phenotype in Saudi Arabian Sickle Cell Anemia. New England Journal of Medicine, 1987, 316, 244-250.	13.9	122
29	Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major. New England Journal of Medicine, 1985, 312, 1600-1603.	13.9	269